Chemical Restraint in U.S. Custody: Trends, Outcomes, and Policy Shifts (2022–2025)

National Data Reveal Increased Use and Changing Patterns of Chemical Restraint

The largest national study to date, published in September 2026 (PMID: 42762283), finds that chemical restraint—defined as the involuntary administration of psychoactive agents to subdue individuals in custody—has increased in frequency across U.S. jurisdictions between 2022 and 2025. The study, drawing on mandatory reporting data from law enforcement, emergency medical services (EMS), and hospital records, identifies ketamine as the most commonly used agent, followed by midazolam and haloperidol. Notably, the study documents a 24% rise in chemical restraint episodes in pre-hospital settings, with marked regional variation and a shift toward rapid-onset dissociative agents.

Mechanisms, Agents Used, and Clinical Outcomes

Chemical restraint in custody typically involves intramuscular or intravenous administration of sedatives or dissociatives to manage agitation or perceived risk to self or others. The study reports that ketamine was used in 62% of documented cases, with dosing protocols varying widely—even within the same jurisdiction. Clinical outcomes analysis reveals that while most patients were stabilized without major incident, 8.7% experienced significant adverse events, including respiratory depression, hypotension, or need for advanced airway management. The study also notes that the risk of adverse outcomes was higher when chemical restraint was administered outside hospital settings, and when combined with physical restraint.

Policy and Oversight Implications: Legal and Ethical Crossroads

The findings underscore a critical policy gap: there is no unified national standard governing the use of chemical restraint in law enforcement or EMS contexts. State-level protocols differ markedly, and oversight is fragmented between health, law enforcement, and judicial authorities. The study’s data suggest that current practices may not align with best-practice guidelines from the American College of Emergency Physicians (ACEP) or the Substance Abuse and Mental Health Services Administration (SAMHSA), particularly regarding agent selection, dosing, and monitoring. The use of ketamine—classified as a Schedule III controlled substance and increasingly researched for therapeutic use—raises unique legal and civil liberties concerns when deployed involuntarily in non-clinical settings. The study’s authors call for federal review of chemical restraint policies, emphasizing the need for standardized training, documentation, and post-incident review to safeguard patient rights and minimize harm.

• Concrete example: The study describes a real-world case in which a lack of clear protocol led to an individual receiving a dose of ketamine above recommended limits, resulting in prolonged intubation and subsequent litigation against both EMS and the municipality. This highlights a failure mode not widely discussed in prior literature: inconsistent dosing and documentation as a driver of both clinical risk and legal exposure.

Risks, Unknowns, and Research Needs

Significant risks remain unresolved: the long-term health impacts of involuntary ketamine administration are poorly characterized, especially in populations with underlying health conditions or polysubstance exposure. The study notes a lack of systematic follow-up on individuals subjected to chemical restraint, limiting understanding of downstream effects such as trauma, medication interactions, or exacerbation of psychiatric symptoms. There is also scant data on the demographic distribution of chemical restraint use, raising concerns about potential disparities by race, age, or mental health status. The authors recommend that future research prioritize longitudinal tracking and equity analysis, and that policymakers consider requiring independent review of all chemical restraint incidents.

Looking Forward: Policy Reform and Research Priorities

The national study’s findings are likely to catalyze debate among policymakers, clinicians, and civil liberties advocates. As the medical and legal landscape for psychoactive substances—including ketamine—continues to evolve, the intersection of emergency medicine, law enforcement, and individual rights demands urgent attention. Concrete next steps could include federal guidance on chemical restraint, investment in non-pharmacologic de-escalation training, and robust data collection on outcomes and disparities. For researchers, the study highlights the need to bridge gaps between clinical trial environments and real-world emergency practice, ensuring that safety, efficacy, and ethical standards are upheld across all settings where psychoactive agents are used involuntarily.

How we research: This post was written and reviewed by Dr. Alex M. Carter, MD, MPH (psychiatry, health policy), on 2026-09-20. Primary source: PubMed/NCBI (PMID: 42762283).